171 results
Page 4 of 9
424B3
ccrpt4oh06sakm78pna
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-10.1
uxg0mm6x9f4knyysxl
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
ncoitx1hywry
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
5brydwn
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
2kexqs11pfanw7v3xa
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
3zpx 3ey2nyx58vuk
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
4vbtdlozdjlaop9 i04q
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
ikabb66089d7hxb6jz1
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
0oxp i9t1jos
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
pgek52 gzts
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
ixqfvogm2ev2w5l
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
vmpuye6ria
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
9836n6m
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
hn7cnmo 1yk
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
dew8rogn8lvko
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-10.1
zedjnrb hyx2kxux
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
ig67go7
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am